Summit Therapeutics

Stock market drop
Favicon Fierce Pharma

Summit shares tumble on interim PD-1/VEGF trial miss

The squamous cohort of ivonescimab's Harmoni-3 in first-line NSCLC apparently missed statistical significance on PFS at an interim analysis.
Angus Liu May 1, 2026 10:56am
merck

AACR: Merck unveils PD-1xVEGF bispecific data in NSCLC

Apr 17, 2026 3:00pm
Pfizer

Pfizer lays out its PD-1xVEGF bispecific research strategy

Nov 11, 2025 11:43am
Akeso
Favicon Fierce Pharma

Akeso, Summit's ivonescimab ups PD-1 in chemo combo in 1L NSCLC

Oct 19, 2025 10:45am
Graphic of a fork in the road with arrows pointing in either direction
Favicon Fierce Pharma

Editor's Corner—Summit must submit to Big Pharma, stat

Sep 10, 2025 2:50pm
Summit
Favicon Fierce Pharma

Summit's global PD-1xVEGF data show new promising OS trend

Sep 7, 2025 3:30am